Financial Performance - The company's operating revenue for Q1 2024 was ¥450,203,926.44, an increase of 11.17% compared to ¥404,959,881.53 in the same period last year[5] - Net profit attributable to shareholders decreased by 20.50% to ¥22,838,254.18 from ¥28,729,049.41 year-on-year[5] - Basic and diluted earnings per share both decreased by 22.22% to ¥0.07 from ¥0.09 in the same period last year[5] - Net profit for Q1 2024 was CNY 24,239,425.41, a decrease of 25.4% from CNY 32,498,774.16 in Q1 2023[25] - The total comprehensive income for Q1 2024 was ¥24,239,425.41, down 25.5% from ¥32,498,774.16 in Q1 2023[26] Cash Flow - The net cash flow from operating activities increased significantly by 378.55%, reaching ¥29,801,550.08, compared to a negative cash flow of -¥10,698,900.14 in the previous year[9] - Cash inflows from operating activities totaled ¥476,468,787.45, a decrease of 29.7% from ¥677,751,066.46 in the previous year[28] - Cash and cash equivalents at the end of Q1 2024 were ¥484,301,578.58, down from ¥682,889,219.70 at the end of Q1 2023[29] - The company reported cash outflows from investing activities of ¥58,012,431.52, compared to ¥73,790,814.76 in the previous year, indicating a reduction in investment spending[28] - Cash outflows from financing activities were ¥193,482,998.20, down from ¥301,900,261.61 in Q1 2023, showing a decrease in financing costs[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,136,447,885.56, a slight decrease of 0.24% from ¥2,141,654,413.64 at the end of the previous year[5] - Total liabilities decreased to CNY 735,838,754.80 from CNY 765,284,708.21, a decline of 3.8%[22] - Accounts receivable increased to CNY 323,385,313.57 from CNY 302,883,199.48, reflecting a growth of 6.5%[22] - Inventory decreased to CNY 70,365,243.82 from CNY 96,320,980.58, a decline of 27.0%[22] - Short-term borrowings decreased to CNY 346,860,946.32 from CNY 393,426,046.79, a reduction of 11.8%[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,229[11] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group, holds 36.42% of the shares, totaling 116,550,000 shares[11] Impairment and Provisions - The company has made a provision for impairment of receivables amounting to ¥56,891,633.89, which will reduce the net profit attributable to shareholders by ¥41,530,892.74 for the first nine months of 2023[12] - The company has estimated a low probability of recovering accounts receivable from a specific client, leading to a provision for bad debts of ¥275,533,742.56, resulting in a cumulative provision balance of ¥292,722,528.83, which is 85% of the total[13] Investments and Projects - The company is constructing the Global Printing Expansion and Green Packaging Intelligent Manufacturing Industrial Park, with the first phase of the project including the completion of infrastructure and partial installation of production lines, laying a solid foundation for production operations in 2024[15] - A new company, Beijing Jinyinlian (Tianjin) New Materials Technology Co., Ltd., has been established with a registered capital of no less than ¥80 million, and a total project investment of no less than ¥100 million for the development and operation of new materials[16] - The company has decided to liquidate its equity investee, Shaanxi Yongxin, due to adverse impacts from rising raw material costs and increased environmental compliance requirements, with the liquidation expected to have minimal impact on the company's business segments[17] Management and Governance - The company completed the election of its sixth board of directors and supervisory board, with a term of three years, and appointed key management personnel including the chairman and general manager[18] Research and Development - The company reported a decrease in research and development expenses to CNY 11,837,435.75 from CNY 14,132,285.59, a reduction of 16.5%[25] Audit and Reporting - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[30]

西安环球印务股份有限公司 2023 年度监事会工作报告 2023 年度公司监事会根据《公司法》、《证券法》、《公司章程》和《公司 监事会议事规则》及其他法律法规的有关规定，本着对全体股东负责的态度，对 公司依法运行情况和董事及高级管理人员的履行职责情况进行监督，为企业的规 范运作和发展起到了积极作用，维护了公司及股东的合法权益。现将监事会的主 要工作报告如下: 西安环球印务股份有限公司 2023 年度监事会工作报 一、监事会工作情况 报告期内，监事会共召开 5 次会议，会议的通知、召开、表决程序以及会议 的提案、议案等符合《公司法》、《公司章程》、《监事会议事规则》等法律、 法规的规定和监管部门的规范要求； （一）2023 年 4 月 28 日，第五届监事会第十二次会议审议通过了以下 15 项议案： 告 1) 《关于审议<2022 年度监事会工作报告>的议案》 2) 《关于审议<2022 年度财务决算报告>的议案》 3) 《关于审议<2023 年度财务预算方案>的议案》 4) 《关于工资总额 2022 年度执行情况及 2023 年度预算的议案》 5) 《关于审议<2022 年度利润分配预案>的议案》 6) 《 ...

西安环球印务股份有限公司2023年度财务决算报告 西安环球印务股份有限公司 2023 年度财务决算报告 2023 年，公司管理层在董事会的坚强领导下，全面落实"两新两运营 高质 量发展"的工作思路，带领全体员工齐心协力抓经营，2023 年主业医药包装板 块主要经营指标均按年初目标任务完成，但互联网数字营销业务受外部经济环境 及国家政策影响，主要指标较上年同期有不同程度的下降。 希格玛会计师事务所（特殊普通合伙）已对公司本年度的财务报表进行了审 计，认为本公司的会计报表已经按照企业会计准则和《企业会计制度》的规定编 制，在所有重大方面公允地反映了公司 2023 年 12 月 31 日的财务状况以及 2023 年度经营成果和现金流量，并为本公司 2023 年度会计报表出具了无解释性说明 的标准无保留意见的审计报告。审计后的决算情况如下： 一、财务报表合并范围 截至 2023 年 12 月 31 日，公司财务报表合并范围内子公司包括： 二、报告期内主要合并财务数据及指标 单位：万元 | 项 目 | 2023 年度/2023 | 2022 年度/2022 | 增减额 | 增减率 | | --- | --- | --- ...

Financial Performance - The company's revenue for Q3 2022 was ¥396,076,142.24, a decrease of 41.99% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥22,782,631.86, down 3.99% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥19,391,107.03, a decline of 7.14% compared to the previous year[4] - Total operating revenue for Q3 2022 was ¥1,401,026,910.63, a decrease of 39.2% compared to ¥2,307,918,790.20 in the same period last year[20] - Net profit for Q3 2022 was ¥95,883,296.21, a decline of 19.2% from ¥118,749,758.29 in Q3 2021[21] - The basic earnings per share for Q3 2022 were ¥0.09, a decrease of 18.18% compared to the same period last year[4] - Earnings per share for Q3 2022 was ¥0.33, compared to ¥0.40 in the same quarter last year[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,830,833,597.44, an increase of 11.80% from the end of the previous year[4] - The company's total assets amounted to approximately CNY 1.83 billion, an increase from CNY 1.64 billion at the beginning of the year[18] - The company's total liabilities increased to ¥894,921,659.65 from ¥793,088,893.48 year-on-year, reflecting a rise of 12.8%[20] - The total equity attributable to shareholders of the parent company rose to ¥841,393,967.60, up from ¥758,397,541.67, indicating an increase of 10.9%[20] Cash Flow - The company reported a net cash flow from operating activities of ¥54,425,322.06, which increased by 17.95% year-to-date[4] - The net cash flow from operating activities for Q3 2022 was ¥54,425,322.06, an increase from ¥46,144,103.80 in Q3 2021, reflecting a growth of approximately 17.8%[23] - Cash flow from operating activities for the current period was ¥2,671,883,867.58, slightly up from ¥2,650,294,570.86 in the previous year[22] - The ending balance of cash and cash equivalents was ¥226,962,636.58, down from ¥257,048,284.26 in the previous year, a decrease of about 11.7%[23] - Cash inflow from financing activities amounted to ¥460,134,408.71, up from ¥360,447,362.99 in Q3 2021, representing an increase of approximately 27.7%[23] - The net cash flow from financing activities was negative at -¥53,296,378.38, contrasting with a positive net cash flow of ¥16,322,547.83 in Q3 2021[23] Investments and Projects - The company is currently constructing a green packaging intelligent manufacturing industrial park in Xi'an, which includes primary and secondary pharmaceutical packaging production centers and a technology R&D center[11] - The company signed a total contracting agreement for the construction project with China Construction Fourth Engineering Bureau[11] - The company received government subsidies amounting to ¥4,745,378.24 during the reporting period, contributing to its non-recurring gains[5] - The company plans to issue up to 68,040,000 A-shares through a private placement, which would account for no more than 27% of the total share capital before the issuance[12] Changes in Financial Metrics - The company's cash and cash equivalents decreased to CNY 241.23 million from CNY 299.36 million at the beginning of the year, reflecting a decline of approximately 19.4%[18] - Accounts receivable stood at CNY 272.46 million, slightly down from CNY 284.45 million, indicating a decrease of about 4.2%[18] - The company reported a significant increase in prepayments, which rose to CNY 436.81 million from CNY 154.37 million, marking an increase of approximately 183.5%[18] - The company’s inventory decreased to CNY 55.83 million from CNY 114.56 million, a decline of about 51.2%[18] - The company’s long-term equity investments increased to CNY 124.60 million from CNY 122.02 million, showing a growth of approximately 2.1%[18] - The company’s fixed assets increased to CNY 272.04 million from CNY 257.12 million, reflecting an increase of about 5.8%[18] Shareholder Actions - The company’s major shareholder, Hong Kong Yuanshi International Co., Ltd., plans to reduce its holdings by up to 15,120,000 shares, representing 6% of the total share capital[15]

Financial Performance - The company's revenue for Q1 2023 was ¥404,959,881.53, a decrease of 24.95% compared to ¥539,587,507.41 in the same period last year[4] - Net profit attributable to shareholders was ¥28,729,049.41, representing an increase of 4.84% from ¥27,402,907.36 year-on-year[4] - The company's net profit for Q1 2023 was not explicitly stated, but the significant decrease in revenue and costs indicates a challenging financial environment[22] - The net profit for Q1 2023 was CNY 32,498,774.16, an increase of 1.79% compared to CNY 31,925,678.59 in Q1 2022[24] - The operating profit for the quarter was CNY 36,058,491.19, slightly up from CNY 35,695,830.95 in the same period last year[24] - The total profit amounted to CNY 35,958,491.19, compared to CNY 35,695,830.96 in Q1 2022, reflecting a growth of 0.74%[24] Cash Flow and Liquidity - The net cash flow from operating activities was -¥10,698,900.14, a decline of 141.46% compared to ¥25,807,505.26 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY -10,698,900.14, a significant decrease from a net inflow of CNY 25,807,505.26 in Q1 2022[27] - Cash flow from investing activities resulted in a net outflow of CNY -73,779,314.12, compared to CNY -7,366,367.50 in the same quarter last year[28] - Cash flow from financing activities recorded a net outflow of CNY -119,900,261.61, worsening from CNY -61,006,303.84 in Q1 2022[28] - Cash and cash equivalents at the end of the reporting period amount to RMB 711,217,748.73, down from RMB 906,522,100.48 at the beginning of the year[19] - The total cash and cash equivalents at the end of the quarter were CNY 682,889,219.70, down from CNY 233,565,112.62 at the end of Q1 2022[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,483,533,511.47, down 4.46% from ¥2,599,603,496.21 at the end of the previous year[4] - Accounts receivable increased to CNY 541,890,087.14 from CNY 446,449,714.46, reflecting a rise of approximately 21%[21] - Total liabilities decreased to CNY 771,114,976.93 from CNY 919,683,735.82, a reduction of about 16%[21] - Inventory decreased by 47.77% to ¥49,875,558.27, attributed to increased sales and reduced stocking[9] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,804[12] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., holds 36.42% of shares, totaling 116,550,000 shares[12] Investments and Projects - Cash paid for fixed asset purchases surged by 742.03% to ¥65,552,148.76, reflecting significant investments in key production equipment[10] - The company is constructing a green packaging smart manufacturing industrial park, which includes primary and secondary pharmaceutical packaging production centers and a technology R&D center[16] - The registered capital for the new materials project company in Tianjin is not less than RMB 80 million, with a total investment of at least RMB 100 million[17] Tax and Expenses - The company’s tax expenses increased by 64.99% to ¥3,118,220.95 due to higher VAT payments[10] - Research and development expenses for Q1 2023 were CNY 14,132,285.59, down from CNY 16,502,638.89, a decrease of approximately 13%[22] Future Outlook - The company plans to focus on market expansion and new product development to enhance future growth prospects[22]

中信证券股份有限公司关于 西安环球印务股份有限公司 部分募投项目延期的核查意见 中信证券股份有限公司（以下简称中信证券或保荐人）作为西安环球印务股 份有限公司（以下简称环球印务或公司）非公开发行股票的保荐人，根据《证券 发行上市保荐业务管理办法》《深圳证券交易所股票上市规则》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》《上市公司监管指引 第 2 号——上市公司募集资金管理和使用的监管要求》等有关法律法规的要求， 对公司部分募投项目延期事项进行了审慎核查。核查的具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准西安环球印务股份有限公司非公开发 行股票的批复》（证监许可〔2022〕397 号）核准，公司向特定对象非公开发行人 民币普通股 68,040,000 股，每股面值 1.00 元，每股发行价格为人民币 11.03 元， 募集资金总额为人民币 750,481,200.00 元，扣除相关发行费用 12,948,580.21 元 （不含税）后，本次非公开发行实际募集资金净额为人民币 737,532,619.79 元。 2022 年 12 月 5 日，希格玛会计师 ...

独立董事述职报告（相征） 2023 年度，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。 二、独立董事年度履职概况 （一）参加股东大会和出席董事会会议情况 2023 年度任职期间，公司共召开了 9 次董事会会议，本人均按时出席会议， 没有缺席或连续两次未亲自出席会议的情况。2023 年度任职期间，本人共参加 1 次股东大会。本着勤勉尽责的原则，本人认真审核了提交董事会的所有议案，主 动了解公司经营情况，并与公司管理层进行了充分的沟通，获取相关信息，以审 慎态度行使表决权，本人认为公司董事会的召集召开符合法定程序，重大经营事 项均履行了相关审批程序，因此，对董事会各项议案均投了赞成票，无提出异议 的事项，没有反对和弃权的情形。 西安环球印务股份有限公司 独立董事 2023 年度述职报告 各位股东及股东代表： 本人作为西安环球印务股份有限公司（以下简称"公司"）的独立董事，在 根据《公司法》、《上市公司独立董事管理办法》、《上市公司独立董事履职指 引》、《上市公司治理准则》、《公司章程》、《公司独立董事工作制度》及有 关法律法规的规定和要求，认真履行职责，充分发挥独立董 ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥539,587,507.41, a decrease of 20.29% compared to ¥676,970,746.02 in the same period last year[4]. - The net profit attributable to shareholders for Q1 2022 was ¥27,402,907.36, down 8.77% from ¥30,036,045.48 in the previous year[4]. - The basic earnings per share for Q1 2022 was ¥0.11, a decrease of 8.33% from ¥0.12 in the same period last year[5]. - The net profit for Q1 2022 was CNY 31,925,678.59, a decrease of 12.5% compared to CNY 36,354,428.69 in Q1 2021[23]. - The operating profit for Q1 2022 was CNY 35,695,830.95, down from CNY 42,192,555.84 in the same period last year, reflecting a decline of 15.5%[23]. - The total comprehensive income for Q1 2022 was CNY 31,925,678.59, down from CNY 36,354,428.69 in the same period last year, reflecting a decrease of 12.5%[24]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥25,807,505.26, compared to a negative cash flow of ¥52,731,812.25 in the same period last year, representing a 148.94% increase[4]. - The total revenue from sales and services received in cash was CNY 647,469,986.06, compared to CNY 691,175,879.11 in the previous year, indicating a decline of 6.3%[27]. - The company reported a total cash outflow from financing activities of CNY 265,719,478.39, compared to CNY 188,911,308.03 in the previous year, indicating an increase of 40.6%[28]. - Cash and cash equivalents at the end of Q1 2022 were CNY 233,565,112.62, down from CNY 274,281,873.94 at the end of Q1 2021[28]. - The cash and cash equivalents decreased to CNY 253,874,088.24 from CNY 299,361,975.03 at the beginning of the year[18]. Assets and Liabilities - The total assets at the end of Q1 2022 were ¥1,627,394,738.32, a slight decrease of 0.62% from ¥1,637,617,535.07 at the end of the previous year[5]. - The total liabilities as of March 31, 2022, were CNY 750,940,418.22, down from CNY 793,088,893.48 at the start of the year[20]. - The company's non-current liabilities decreased to CNY 46,212,111.38 from CNY 52,048,370.07 at the beginning of the year[20]. - The equity attributable to shareholders increased by 3.61% to ¥785,800,449.03 from ¥758,397,541.67 at the end of the previous year[5]. - The company's retained earnings increased to CNY 446,548,767.31 from CNY 419,145,859.95 at the beginning of the year[20]. Operational Developments - The company is expanding its production capacity with a new green packaging intelligent manufacturing industrial park project in Xi'an, which includes a primary and secondary pharmaceutical packaging production center and a technology R&D center[13]. - The company has signed a construction project general contracting contract with China Construction Fourth Engineering Bureau for the new industrial park[13]. - The company has strengthened its collection of accounts receivable, contributing to the improved cash flow from operating activities despite a decline in revenue[8]. Research and Development - Research and development expenses amounted to CNY 16,502,638.89, a decrease of 32.1% from CNY 24,341,072.20 in Q1 2021[23]. Share Issuance - The company plans to issue up to 68,040,000 shares through a non-public offering, which will not exceed 27% of the total share capital before the issuance[14]. - The company received approval from the China Securities Regulatory Commission for the non-public offering on March 2, 2022[14].

证券代码：002799 证券简称：环球印务 公告编号：2024-022 西安环球印务股份有限公司 关于2024年度公司为控股子公司提供担保额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《证券法》、《公司法》和《深圳证券交易所股票上市规则》的有关规 定，西安环球印务股份有限公司（以下简称"公司"、"环球印务"、"本公 司"）于 2024 年 4 月 25 日召开了第六届董事会第三次会议、第六届监事会第三 次会议，审议通过《关于 2024 年度公司为控股子公司提供担保额度的议案》， 现将有关事项公告如下： 一、担保情况概述 为保证公司子公司天津滨海环球印务有限公司（以下简称"天津环球"）、霍 尔果斯领凯网络科技有限公司及其控股子公司（以下简称"领凯科技及其控股子 公司"）、北京金印联国际供应链管理有限公司及其控股子公司（以下简称"金印 联及其控股子公司"）、西安凌峰环球印务科技有限公司（以下简称"凌峰环球"） 的正常生产、经营需要，公司对 2024 年度子公司拟向金融机构申请授信额度 5 亿元、向合作供应商申请赊销额度 1.12 亿元事项提供担保 ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,600,910,936, a decrease of 17.07% compared to CNY 1,930,489,320 in 2022[21] - The net profit attributable to shareholders of the listed company was CNY 221,928,603, representing a decline of 356.29% from CNY 106,357,144 in the previous year[21] - Basic and diluted earnings per share were both CNY -0.69, a decrease of 302.94% from CNY 0.36 in 2022[21] - The weighted average return on net assets was -15.11%, down from 11.22% in the previous year[21] - Total assets decreased by 17.62% to CNY 2,599,701,360 from CNY 2,604,514,570[22] - Net profit attributable to shareholders decreased by 14.42% to CNY 1,582,517,660 from CNY 1,586,106,870[22] - The company reported a total operating cost of ¥1,356,209,316, which is a reduction of 17.86% year-over-year[79] - The company reported a significant increase of 343.20% in construction in progress to 414,839,786, mainly for subsidiary projects and equipment purchases[98] Cash Flow and Investments - The net cash flow from operating activities increased significantly to CNY 134,527,227, a rise of 593.24% compared to CNY 27,273,965 in 2022[21] - The company reported a net cash flow from operating activities of CNY -10,698,900.14, compared to CNY 78,092,342.92 in the previous year[28] - Investment cash inflow surged by 12,514.84% to ¥1,452,899.26, primarily due to received dividend payments[91] - Investment cash outflow increased by 219.89% to ¥310,144,484.02, mainly due to engineering expenses paid by subsidiaries[92] - The net increase in cash and cash equivalents was negative at -¥351,293,488.63, a decline of 157.48% compared to the previous year[91] - The company has committed to invest a total of 73,753 million CNY in various projects, with 49,023 million CNY already utilized by the end of the reporting period[111] Research and Development - The company has maintained its commitment to research and development, focusing on new product innovations and technology advancements[21] - The company is focusing on high-efficiency automation, low-carbon green development, and digital intelligence in its R&D efforts[84] - The company has completed multiple anti-counterfeiting technology developments, with some products already applying these technologies in mass production[85] - R&D investment decreased by 26.17% to ¥47,046,363.74, accounting for 2.94% of operating revenue[88] - The number of R&D personnel decreased by 19.05% to 153, with a proportion of 14.81%[88] Market Strategy and Expansion - The company is exploring market expansion opportunities to enhance its competitive position[21] - The company aims to expand its market presence in the fast-moving consumer goods packaging sector, targeting medical devices, health care products, and cosmetics[85] - The company is focusing on developing new products such as low-odor coatings and antibacterial coatings to enhance market competitiveness[88] - The company plans to expand its production capacity and implement smart manufacturing projects to achieve digital and intelligent upgrades, ensuring growth in pharmaceutical and consumer goods packaging[130] - The company is committed to exploring new forms of internet digital marketing, investing in commercial data and technology product development to strengthen its competitive advantage[132] Risk Management - The company has outlined potential risks in its future development outlook, urging investors to be cautious[4] - The company faces risks from national policy adjustments affecting the pharmaceutical and consumer goods packaging industries, which could impact its operational status[140] - The company acknowledges the risk of intensified competition in the pharmaceutical and consumer goods packaging sectors, which may affect its future strategic development[141] - The company is aware of the risks associated with raw material price fluctuations and is implementing strategies to manage supply chain costs effectively[148] Corporate Governance and Management - The company experienced a leadership change with the resignation of the chairman Li Yiling due to reaching the legal retirement age on January 10, 2023[178] - The company appointed a new general manager, Xia Shunwei, on August 28, 2023, following the resignation of Sun Xuejun[180] - The board of directors will undergo a re-election process on January 4, 2024, to ensure effective corporate governance[179] - The company has implemented a performance-based salary system for its directors and senior management, linking remuneration to annual operating performance and personal assessments[195] Environmental Commitment - The company is committed to green production and smart manufacturing, investing in environmental protection and digital transformation of production equipment[46] - The company has maintained a B-level environmental performance rating in Shaanxi Province and has upgraded its waste gas treatment equipment, enhancing its competitive advantage in environmental protection[50] Client and Market Relationships - The company has established long-term partnerships with major pharmaceutical firms, including several Fortune 500 companies, ensuring a stable growth trajectory in the pharmaceutical packaging sector[44] - The company serves over 800 clients across various industries, including e-commerce, gaming, education, finance, and internet, continuously improving its marketing service capabilities and data analysis[53] - The company has successfully collaborated with high-quality clients such as Betaini, Giant Bio, and L'Oreal, enhancing its market presence[126]